Cerus Corporation Announces Contract with Canadian Blood Services for INTERCEPT Blood System for Platelets

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Cerus Corporation (Nasdaq:CERS) today announced its contract with Canadian Blood Services for the INTERCEPT Blood System for Platelets. Canadian Blood Services is one of Canada’s two blood operators, serving all Canadian provinces and territories except Quebec.

“Today’s announcement is a significant milestone for Cerus as we enter the Canadian market. We are proud to partner with Canadian Blood Services to introduce pathogen inactivated platelets in Canada,” said Christian Boutemy, Cerus’ vice president, commercial operations EMEA, who is also responsible for Canada. “For nearly 30 years, Cerus has been dedicated to safeguarding the blood supply around the globe. We are pleased that Canadian Blood Services is taking this step to bring INTERCEPT to Canadians. We look forward to supporting them as they scale up production of pathogen inactivated platelets for patients throughout the region.”

“As an organization, we are committed to ensuring high quality blood components and to minimizing the risk of transfusion-transmitted infections. The INTERCEPT Blood System allows us to deliver on this goal,” said Dr. Graham D. Sher, Canadian Blood Services’ chief executive officer. “Our aim is to drive full adoption of pathogen reduced platelets once INTERCEPT is deployed across all of our production sites.”

Canadian Blood Services intends to implement pathogen reduced platelets in a gradual and measured manner, beginning in the Ottawa region in Fall 2021 subject to Health Canada approval. Broader implementation will begin after Cerus has attained Canadian regulatory approval for extension of pathogen reduced platelets’ shelf life from five days to seven.

Canadian Blood Services manufactures approximately 115,000 platelet doses annually.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles